COMMUNICATION
Protein Kinase B/akt and Rab5 Mediate Ras Activation of Endocytosis*

M. Alejandro BarbieriDagger §, Aimee D. Kohn, Richard A. Roth, and Philip D. StahlDagger parallel

From the Dagger  Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri 63110 and the  Department of Molecular Pharmacology, Stanford University School of Medicine, Palo Alto, California 94305

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Transient expression of oncogenic Ha-Ras (Ras:V12) stimulates endocytosis. Using NIH3T3 cells expressing constitutively active protein kinase B/akt (PKB/akt) or kinase-dead PKB/akt, we show that PKB/akt mediates the stimulatory effect of Ras on endocytosis. Fluid phase endocytosis of horseradish peroxidase in cells expressing the constitutively active form of PKB/akt was elevated and insensitive to phosphatidylinositol 3-kinase inhibitors. However, expression of dominant negative Rab5:N34 blocked endocytosis in cells expressing the constitutively active form of PKB/akt.

Transient expression of either Rab5:wt or Rab5:L79, a GTPase deficient mutant of Rab5, in cells expressing constitutively activated PKB/akt further increased endocytic rate. However, in cells expressing kinase-dead PKB/akt, endocytic rate was not affected by transient expression of Rab5:wt. Rab5:L79, on the other hand, increased endocytosis in cells expressing kinase-dead PKB/akt. Similar results were obtained using an in vitro endosome fusion reconstitution assay with cytosol prepared from cells expressing the activated PKB/akt or kinase-dead PKB/akt. Both Rab5:wt and Rab5:L79 stimulated endosome fusion when assayed in cytosol containing the activated PKB/akt, whereas only Rab5:L79 activated fusion when the assay utilized cytosol from kinase-dead expressing cells. We conclude that Ras activation of endocytosis requires both PKB/akt and Rab5 and that active kinase is required for activation Rab5.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Endocytosis is a carefully orchestrated process required by all cells for nutrition and defense. Whereas an increasing number of Rab GTPases localize to the endocytic pathway, including Rab5, Rab4, Rab11, and Rab7 (1), the endocytic rate appears to be regulated by Rab5 (2). Earlier work has shown that Rab5, in turn, is regulated by upstream factors, including phosphatidylinositol 3-kinase and Ras (3, 4). PKB/akt1 is a serine threonine kinase that has emerged as a key intermediate between signal transducing growth factor receptors, including insulin (4) and platelet-derived growth factor (6, 7) and a variety of downstream effectors (8, 9). Recent work has linked PKB/akt to such diverse processes as cell survival by suppressing apoptosis via phosphorylation of BAD (10) and the metabolic response to insulin via the regulation of intracellular trafficking of vesicles containing Glut 4 (11). Activation of PKB/akt requires phosphorylation of the kinase by at least two phosphoinositide-dependent kinases that phosphorylate PKB/akt at Thr308 and Ser473 (12, 13). Known downstream targets of PKB/akt include p70 S6 kinase (6, 7) and glycogen synthase kinase (14), although many other targets most likely exist given that PKB/akt is present in at least three isoforms (8, 9). Here we demonstrate that Rab5, a GTPase that is rate-limiting for endocytosis, is regulated by PKB/akt, a kinase coupled to signal transduction. Moreover, we demonstrate that the endocytic response to "activated Ha-Ras" requires both PKB/akt and Rab5.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

Materials-- Dinitrophenol (DNP)-derivatized beta -glucuronidase (DNP-beta -glucuronidase) and aggregated anti-dinitrophenol IgG (anti-DNP IgG) were prepared as reported (15). Anti-Rab5, 4F11 monoclonal antibody was a generous gift of Angela Wandinger-Ness, Northwestern University, Chicago. All other reagents were obtained from Sigma, except where indicated. LY-294002 was a generous gift of Dr. C. J. Vlahos.

Sindbis Virus Constructs and NIH3T3 Cell Lines-- For overexpression, NIH3T3 cell monolayers in 35-mm dishes (~5 × 105 cells/dish) were infected with either the vector Sindbis virus as a negative control or the recombinant Sindbis encoding Ras:V12, Rab5:wt, or Rab:L79 (16). High multiplicity of infection (80 plaque-forming units/cell) was employed to ensure that all of the cells were infected (16). NIH3T3 cells stably expressing PKB(akt)-HA constructs were generated by retroviral infection as described previously (11).

Endocytosis Assay-- Fluid phase endocytosis of HRP was performed as described (16). Twenty-four h after withdrawal of serum, NIH3T3 cell monolayers in 35-mm dishes were washed three times with serum-free alpha -MEM, and HRP endocytosis was initiated by addition of 1 ml of alpha -MEM containing 2 mg/ml HRP and 0.2% (w/v) bovine serum albumin at 37 °C. To estimate HRP uptake, the cells were washed three times with phosphate-buffered saline (PBS), trypsinized on ice for 20 min, washed two times with PBS, and lysed in 500 µl of lysis buffer (3). Cell lysates were assayed for HRP activity as described (3).

Rab5 and in Vitro Endosome Fusion-- Rab5 was prepared in large quantity as a glutathione S-transferase fusion proteins in Escherichia coli strain JM 101, and the GST-Rab5 proteins were affinity-purified by glutathione-Sepharose chromatography as described previously (16). GST-Rab5 (1 µM) was prenylated by incubation with semipurified REP-1/Rab geranylgeranyltranferase in 50 µl of 50 mM Hepes/KOH, pH 7.2, 5 mM MgCl2, 0.05 mM Nonidet P-40, 1 mM DTT (buffer A) containing 2 µM geranylgeranyl pyrophosphate for 30 min at 37 °C as described (17, 18). After the reaction, the prenylated Rab5 proteins were directly used as indicated in each figure. Early endosomes, prepared from J774 E-clone macrophages, were loaded with anti-DNP mouse monoclonal antibody or with DNP-beta -glucuronidase as described (15). In vitro reconstitution of fusion was performed as described (15).

Determination of Protein Kinase B/akt Activity and the GTP/GDP Ratio of Rab5 in Cultured Cells-- To determine protein kinase B/akt activity, cells were washed twice with ice-cold PBS and lysed for 20 min at 4 °C in lysis buffer (20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 10% glycerol, 1% Nonidet P-40, 50 mM beta -glycerophosphate, 10 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, and 2 µg/ml leupeptin). The lysates were centrifuged for 10 min at 12,000 × g at 4 °C and assayed as described by Kohn et al. (5).

To determine the ratio of GTP to GDP bound to Rab5 (GTP/GDP ratio), confluent (~5 × 105 cells/dish) NIH3T3 control cells and NIH3T3 expressing constitutively active PKB/akt or kinase-dead PKB/akt were incubated in alpha -MEM phosphate-free medium for 3 h with 300 µCi of 32Pi (200 mCi/mmol, Amersham Pharmacia Biotech). After incubation, the cells were lysed as described (19), and Rab5 was immunoprecipitated using a 4F11 monoclonal antibody bound to the protein A-Sepharose (Amersham Pharmacia Biotech) for 10 min at 4 °C in lysis buffer (20). The beads were washed three times with wash buffer (20 mM Tris-Cl, 0.1% Nonidet P-40, 500 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 1 mM DTT, 1 mg/ml bovine serum albumin, 50 mM beta -glycerophosphate, 10 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, and 2 µg/ml leupeptin) and three times with wash buffer containing 0.001% SDS. The bound nucleotides were then eluted in 12 µl of buffer (10 mM EDTA, 1 mM DTT, 0.1% SDS, 5 mM GDP, 5 mM GTP) for 3 min at 65 °C. All the manipulations, from lysis of the sample to elution of the nucleotides bound to Rab5, were carried out at 4 °C within 40 min. Four-µl samples were then spotted onto 0.1 mm polyethyleneimine-cellulose TLC (Merck) plates, which were developed for 60 min in 0.75 M phosphate, pH 3.4. The samples were dried and placed in autoradiography cassettes. For visualization of the 32Pi-labeled GTP and GDP, films were exposed at -80 °C for 24-36 h. A phosphoimager was used to determine the GTP/GDP ratio.

    RESULTS AND DISCUSSION
Top
Abstract
Introduction
Procedures
Results & Discussion
References

To examine endocytosis in cells expressing constitutively activated or kinase-dead PKB/akt, cells were starved for serum overnight prior to initiating endocytosis assays or transiently expressing Ras or Rab5 constructs. As shown in Fig. 1A, transient expression of Ras:V12 in control cells results in enhanced endocytosis of HRP, a fluid phase endocytosis marker. Expression of Ras:N17, the dominant negative mutant, modestly reduced endocytosis (Fig. 1A). Ras is known to interact with multiple target molecules via its effector domain, including the 110-kDa subunit of phosphatidylinositol 3-kinase (21). Activation of the phosphatidylinositol 3-kinase by Ras:V12 results in increased production of several lipid products. These include phosphatidylinositol 3,4-diphosphate and phosphatidylinositol 3,4,5-triphosphate, which are thought to activate, directly or indirectly, several downstream effectors such as p70 S6 kinase, Rac1, PKC, RalB, and PKB/akt (21-28). To establish a connection between elevated endocytosis observed following activation of the Ras/phosphatidylinositol 3-kinase pathway and the activation of PKB/akt, a downstream target of phosphatidylinositol 3-kinase, we asked whether activation of PKB/akt was directly coupled to endocytosis. NIH3T3 cells were stably transfected with constructs encoding constitutively active or kinase-dead constructs of PKB/akt. Activation was accomplished by addition of the Src myristoylation sequence to the N terminus of PKB/akt (28). A kinase-dead construct was prepared by introducing a point mutation (K179M) at a site required for kinase activity (28). Cells expressing constitutively active PKB/akt demonstrated substantially higher endocytic rates (Fig. 1A), which were similar to the elevated levels observed following expression of Ras:V12 (Fig. 1A). In contrast, cells expressing the kinase-dead construct of PKB/akt (Fig. 1A) showed depressed levels of HRP uptake. To explore the linkage between Ras and PKB/akt, cells were infected with Sindbis virus encoding Ras:V12 and Ras:N17. Overexpression of either activated or dominant negative Ras in cells expressing kinase-dead PKB/akt had no effect on HRP endocytosis, suggesting that activation of PKB/akt is required for Ras stimulation of endocytosis. Moreover, transient expression of either Ras construct (Ras:V12 or Ras:N17) in cells expressing constitutively active PKB/akt had no effect on endocytosis (Fig. 1A). These data suggest that activation of PKB/akt is linked to Ras stimulation of endocytosis and that PKB/akt lies downstream of Ras. Consistent with this proposal, expression of dominant negative Ras:N17 was unable to block the enhanced endocytic rate observed in cells expressing the constitutively active PKB/akt (Fig. 1A). Ras:V12-stimulated endocytosis is inhibited by phosphatidylinositol 3-kinase inhibitors (3, 4). PI 3-kinase activity is known to be required for Ras to stimulate PKB/akt (8, 9). Thus, we found that the phosphatidylinositol 3-kinase inhibitor LY294002 completely inhibited the activation of PKB/akt by Ras:V12 in NIH3T3 cells and substantially reduced the endocytic response (data not shown). The time course of HRP endocytosis in control cells and in cells expressing constitutively active PKB/akt and kinase-dead PKB/akt is shown in Fig. 1B. Constitutively active PKB/akt enhanced both the rate of internalization and the accumulation of internalized HRP. In cells expressing the constitutively active PKB/akt, wortmannin had no effect on endocytosis of HRP (Fig. 1C). This result is consistent with the observation that phosphatidylinositol 3-kinase inhibitors had no effect on the activity of activated PKB/akt.2 These results clearly indicate that PKB/akt is a downstream effector of the Ras/phosphatidylinositol 3-kinase pathway and a key regulator of endocytosis.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 1.   Stimulation of HRP uptake by PKB/akt kinase. A, confluent NIH3T3 cells and NIH3T3 cells expressing the constitutively active PKB/akt or kinase-dead PKB/akt were infected with either the Sindbis vector (V) as a control or the recombinant Sindbis virus encoding Ras:N17 or Ras:V12. At 4 h postinfection, endocytosis was determined by incubating cells with HRP (2 mg/ml; 1 h at 37 °C) as described (16). Values are the mean of three determinations. Vertical lines indicate S.D. for each sample. B, endocytosis in confluent NIH3T3 cell monolayers expressing the constitutively active PKB/akt (AKT+) (bullet ) and kinase-dead PKB/akt (AKT-) (black-square). Cells were incubated at 37 °C for 1 h with HRP (2 mg/ml), and uptake was determined as described (16). Untransfected NIH3T3 cells served as controls (open circle ). The data are representative of five independent experiments. C, effect of wortmannin on endocytosis in confluent NIH3T3 control cells () and NIH3T3 cells expressing the constitutively active PKB/akt (black-square). The cells were treated for 15 min with the indicated concentrations of wortmannin, and uptake of HRP (37 °C; 1 h) was determined (16). The data are representative of four independent experiments.

Following the internalization step at the plasma membrane, endocytic vesicles access the early endocytic sorting compartment by fusion, a process that is regulated by the GTPase Rab5 (2). Rab5 is rate-limiting for endocytosis and for endosome fusion reconstituted in vitro (2, 29, 30). Previous work has demonstrated that elevated endocytosis following overexpression of Rab5 is dependent on phosphatidylinositol 3-kinase (3, 4). Phosphatidylinositol 3-kinase appears to be required for the activation of Rab5, because enhanced endocytosis following expression of Rab5:L79, the GTPase-defective mutant, was unaffected by phosphatidylinositol 3-kinase inhibitors (3, 4). Similar results have been obtained with the in vitro endosome fusion assay (3, 4). The insensitivity of Rab5:Q79L-induced endocytosis to inhibitors of PI 3-kinase following transient expression in cultured cells is confirmed in Fig. 2A. However, recent work by Jones et al. (31) indicates that under some circumstances, the sensitivity of Rab5:Q79L-induced in vitro endosome fusion to wortmannin is substantially reduced, suggesting that PI 3-kinase and guanine nucleotide exchange on Rab5 may not be in a linear pathway. However, the in vitro assay employed by Jones et al. (31) varied substantially from that used in the initial report (3), which showed that stimulation of fusion with Rab5:Q79L was wortmannin-insensitive. Clearly, more work will be needed to sort out the relationship between PI 3-kinase and activation of Rab5. To address whether the stimulation of endocytosis by PKB/akt requires Rab5 activity, we examined the effect of Rab5:wt and Rab5 mutants on HRP uptake in NIH3T3 cells (Fig. 2A) overexpressing constitutively active PKB/akt (Fig. 2B) or kinase-dead PKB/akt (Fig. 2C). Confluent NIH3T3 cell monolayers were infected with recombinant Sindbis viruses encoding Rab5:wt, Rab5:N34, or Rab5:L79 or the Sindbis vector as a control. At 4 h postinfection, cells were treated with LY294002, and HRP uptake was assayed. As expected, the overexpression of Rab5:wt and Rab5:L79 in NIH3T3 cells induced a significant increase in HRP uptake (Fig. 2A). Both expression of Rab5:N34, the dominant negative mutant (data not shown), and the addition of phosphatidylinositol 3-kinase inhibitors (LY294002) blocked Rab5:wt-stimulated and basal HRP uptake (Fig. 2A). However, in cells expressing constitutively active PKB/akt (Fig. 2B) phosphatidylinositol 3-kinase inhibitors had no effect on the activation of endocytosis following expression of either Rab5:wt or Rab5:L79. Expression of Rab5:N34, the dominant negative mutant, significantly blocked HRP uptake (data not shown). In NIH3T3 cells expressing kinase-ead PKB/akt, Rab5:wt was unable to stimulate HRP uptake, when overexpressed with the Sindbis expression vector (Fig. 2C). Rab5:L79, on the other hand, was fully active when expressed in cells stably expressing kinase-ead PKB/akt (Fig. 2C). Thus, it appears that an active PKB/akt is required for Rab5:wt to produce its effects on endocytosis. Rab5 is active in the GTP form. To address whether the expression of active and kinase-dead forms of PKB/akt affects the guanine nucleotide status of Rab5, we determined the ratio of GTP and GDP bound to Rab5 in control cells and in cells expressing the constitutively active PKB/akt or kinase-dead PKB/akt. As shown in Fig. 2D, cells were labeled with 32Pi for 3 h, after which the cells were lysed, and Rab5 was immunoprecipitated as described under "Experimental Procedures." In Fig. 2D, we show that a significant increase in the GTP-bound to Rab5 in cells expressing the constitutively active PKB/akt and a decrease in GTP bound to Rab5 in cells expressing the kinase-dead PKB/akt. These observations are consistent with the fact that the Rab5 dominant negative mutant (Rab5:N34) blocked endocytosis in cells expressing constitutively active PKB/akt (Fig. 2B).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of phosphatidylinositol 3-kinase inhibitors on the HRP uptake in cells co-expressing PKB/akt kinase and Rab5. Confluent NIH3T3 control cells (A) and NIH3T3 expressing constitutively active PKB/akt (B) in 35-mm dishes were infected with either the Sindbis virus vector or the recombinant virus expressing Rab5:wt or Rab5:L79. After 4-h incubation, the cells were treated for 15 min with 50 µM LY294002, and HRP uptake was measured as described in tje legend to Fig. 1. C, confluent NIH3T3 expressing kinase-dead PKB/akt were infected with either Sindbis virus vector or the recombinant virus encoding Rab5:wt or Rab5:L79. HRP uptake was measured as described in the legend to Fig. 1. D, effect of the expression of PKB/akt mutants on the guanine nucleotide status of Rab5. Confluent NIH3T3 control cells, NIH3T3 cells expressing the constitutively active PKB/akt, or kinase-dead PKB/akt were labeled with 32Pi, and Rab5 was immunoprecipitated and analyzed as described under "Experimental Procedures." The total radioactivity recovered on the beads using anti-Rab5 monoclonal antibody was 6132 ± 157 (control), 6211 ± 97(activated PKB/akt) and 6198 ± 197 (kinase PKB/akt). The radioactivity recovered using an irrelevant antibody was less than 2% of that in the presence of anti-Rab5 antibody. Values are mean of two determinations. Vertical lines indicate S.D. for each sample.

Given the inhibitory effect of the kinase-dead PKB/akt mutant on HRP uptake and the insensitivity of the constitutively active PKB/akt to phosphatidylinositol 3-kinase inhibitors, our results suggested a direct involvement of PKB/akt in endocytosis. To confirm these observations, we took advantage of the in vitro endosome fusion by testing directly whether cytosol prepared from cells overexpressing constitutively active PKB/akt or kinase-dead PKB/akt would support fusion. Early endosomes, prepared from J774 E-clone macrophages, were loaded with aggregated monoclonal anti-DNP mouse IgG (via the Fc receptor) or with DNP-beta -glucuronidase (via the mannose receptor) as described (15). Endosomes were incubated with cytosol from control NIH3T3 cells or cells expressing constitutively active PKB/akt or kinase-dead PKB/akt. Endosome fusion with cytosol from cells expressing the constitutively active PKB/akt was elevated compared with control cytosol. However, unlike control cytosol, the endosome fusion with cytosol from cells expressing constitutively active PKB/akt was wortmannin-insensitive (Fig. 3A). Cytosol from cells expressing kinase-dead PKB/akt was poorly active in the in vitro assay (Fig. 3A). PKB/akt-enriched cytosol-stimulated endosome fusion had all the requirements of the standard endosome fusion assay (e.g. ATP, temperature). Importantly, PKB/akt-stimulated endosome fusion was blocked by the Rab5:N34 mutant (Fig. 3B). Furthermore, the addition of Rab5:L79, but not Rab5:wt, to cytosol containing kinase-dead PKB/akt substantially stimulated endosome fusion (Fig. 3C). Taken together, these data suggest that Ras regulates endocytosis via PKB/akt and Rab5 and that the target PKB/akt action is probably guanine nucleotide exchange on Rab5. Ras is reported to have a variable effect on PKB/akt activation by growth factors. In some cases, dominant negative Ras has been found to block growth factor-induced stimulation of PKB/akt, whereas in others, such effects have not been reported (6, 7). This probably reflects the complexity of the regulation of phosphatidylinositol 3-kinase, which is controlled by multiple signaling pathways (8, 9). Furthermore, the closely related protein R-Ras can stimulate both phosphatidylinositol 3-kinase and PKB/akt without affecting the well characterized Ras target, Raf (8, 9). Thus, the activation of PKB/akt may ensure tight regulation of Rab5 function, possibly via guanine nucleotide exchange at the correct membrane localization site during the endocytic cycle to coordinate the assembly and function of macromolecular complexes necessary for endosome fusion.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 3.   Involvement of PKB/akt kinase in early endosome fusion. The in vitro endosome fusion assay was conducted as described (15). A, effect of cytosol concentration on in vitro endosome fusion carried out with cytosols prepared from different sources: control cytosol (, black-square), cytosol from NIH3T3 cells expressing constitutively active PKB/akt (bullet , open circle ), or kinase-dead PKB/akt (black-triangle) in the presence (black-square, bullet ) or the absence (, open circle ) of 50 µM LY294002. The data are representative of four independent experiments. B, characterization of in vitro endosome fusion with cytosol from control NIH3T3 cells or cells expressing constitutively active PKB/akt. Fusion was expressed as a percentage of that obtained with untreated endosomes resuspended in complete fusion buffer supplemented with 1 mg/ml of cytosol and incubated for 45 min at 37 °C. The following conditions were tested: -ATP, depleting system (5 mM mannose, 60 units/ml hexokinase) was substituted for the ATP-regenerating system (i.e. ATP, creatine phosphate, and creatine phosphokinase); +Rab5:N34, 200 nM of prenylated Rab5:N34-REP (Rab escort protein) complex was added to fusion reaction (29); Temperature, in vitro endosome fusion when the reaction was carried out at 4 °C. Values are the mean of three determinations. Vertical lines indicate S.D. for each sample. C, in vitro endosome fusion experiments supplemented with 1 mg/ml cytosol protein prepared from NIH3T3 cells expressing kinase-dead PKB/akt in the presence of different concentrations either Rab5:wt-REP complex (open circle ) or Rab5:L79-REP complex (bullet ). Values are the mean of three determinations. Vertical lines indicate S.D. for each sample.

    ACKNOWLEDGEMENTS

We thank Rita Boshans, Libby Peters, Cheryl Adles, and Marilyn Levy for the excellent technical assistance and Crislyn D'Souza-Schorey for helpful comments.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants DK34926 (to R. A. R.) and GM42259 and DK20579 (to P. D. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Supported by a National Institutes of Health Individual Fellowship.

parallel To whom correspondence should be addressed. Tel.: 314-362-6950; Fax: 314-362-1490; E-mail: pstahl{at}cellbio.wustl.edu.

1 The abbreviations used are: PKB/akt, protein kinase B; DNP, dinitrophenol; HRP, horseradish peroxidase; MEM, minimal essential medium; PI, phosphatidylinositol.

2 M. A. Barbieri, R. Roth, and P. D. Stahl, unpublished observations.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results & Discussion
References

  1. Novick, P., and Zerial, M. (1997) Curr. Biol. 9, 496-504
  2. Bucci, C., Parton, R. G., Mather, I. H., Stunnenberg, H., Simons, K., Hoflack, B., and Zerial, M. (1992) Cell 70, 715-728[Medline] [Order article via Infotrieve]
  3. Li, G., D'Souza-Schorey, C., Barbieri, M. A., Roberts, R. L., and Stahl, P. D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10207-10211[Abstract]
  4. Li, G., D'Souza-Schorey, C., Barbieri, M. A., Cooper, J. A., and Stahl, P. D. (1997) J. Biol. Chem. 272, 10337-10340[Abstract/Free Full Text]
  5. Kohn, A. D., Kovacina, K. S., and Roth, R. A. (1995) EMBO J. 14, 4288-4295[Abstract]
  6. Burgering, B. M. T., and Coffer, P. J. (1994) Nature 376, 599-602
  7. Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., Kaplan, D. R., and Tsichlis, P. N. (1995) Cell 81, 727-736[Medline] [Order article via Infotrieve]
  8. Marte, B. M., and Downward, J. (1997) Trends Biochem. Sci. 22, 355-358[CrossRef][Medline] [Order article via Infotrieve]
  9. Marte, B. M., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H., and Downward, J. (1997) Curr. Biol. 7, 63-70[Medline] [Order article via Infotrieve]
  10. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. (1997) Cell 91, 231-241[Medline] [Order article via Infotrieve]
  11. Kohn, A. D., Summers, S. A., Birnbaum, M. J., and Roth, R. A. (1996) J. Biol. Chem 271, 31372-31378[Abstract/Free Full Text]
  12. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., and Cohen, P. (1997) Curr. Biol. 7, 261-269[Medline] [Order article via Infotrieve]
  13. Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F., and Hawkins, P. T. (1997) Science 277, 567-570[Abstract/Free Full Text]
  14. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Nature 378, 785-789[CrossRef][Medline] [Order article via Infotrieve]
  15. Diaz, R., Mayorga, L., and Stahl, P. (1988) J. Biol. Chem. 263, 6093-6100[Abstract/Free Full Text]
  16. Li, G., Barbieri, M. A., Colombo, M. I., and Stahl, P. D. (1994) J. Biol. Chem. 269, 14631-14635[Abstract/Free Full Text]
  17. Barbieri, M., Li, G., Mayorga, L. S., and Stahl, P. D. (1996) Arch. Biochem. Biophys. 326, 64-72[CrossRef][Medline] [Order article via Infotrieve]
  18. Seabra, M. C. (1996) J. Biol. Chem. 271, 14398-14404[Abstract/Free Full Text]
  19. Datta, K., Franke, T. F., Chan, T. O., Makris, A., Yang, S. I., Kaplan, D. R., Morrison, D. K., Golemis, E. A., and Tsichlis, P. N. (1995) Mol. Cell. Biol. 15, 2304-2310[Abstract]
  20. Stenmark, H., Parton, R. G., Steele-Mortimer, O., Lutcke, A., Gruenberg, J., and Zerial, M. (1994) EMBO. J. 13, 1287-1296[Abstract]
  21. Rodriguez-Viciana, P., Warne, P. H., Vanhaesebroeck, B., Waterfield, M. D., and Downward, J. (1996) EMBO J. 15, 2442-2451[Abstract]
  22. Chung, J., Grammer, T. C., Lemon, K. P., Kazlauskas, A., and Blenis, J. (1994) Nature 370, 71-75[CrossRef][Medline] [Order article via Infotrieve]
  23. Hawkins, P. T., Eguinoa, A., Qiu, R. G., Stokoe, D., Cooke, F. T., Walters, R., Wennstrom, S., Claesson-Welsh, L., Evans, T., and Symons, M. (1995) Curr. Biol. 5, 393-403[Medline] [Order article via Infotrieve]
  24. Toker, A., Meyer, M., Reddy, K. K., Falck, J. R., Aneja, R., Aneja, S., Parra, A., Burns, D. J., Ballas, L. M., and Cantley, L. C. (1994) J. Biol. Chem. 269, 32358-32367[Abstract/Free Full Text]
  25. Nakanishi, H., Brewer, K. A., and Exton, J. H. (1993) J. Biol. Chem. 268, 13-16[Abstract/Free Full Text]
  26. Jones, P. F., Jakubowicz, T., Pitossi, F. J., Maurer, F., and Hemmings, B. A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4171-4175[Abstract]
  27. Coffer, P. J., and Woodgett, J. R. (1991) Eur. J. Biochem. 201, 475-481[Abstract]
  28. Kohn, A. D., Takeuchi, F., and Roth, R. A. (1996) J. Biol. Chem. 271, 21920-21926[Abstract/Free Full Text]
  29. Li, G., and Stahl, P. D. (1993) J. Biol. Chem. 268, 24475-24480[Abstract/Free Full Text]
  30. Barbieri, M. A., Li, G., Colombo, M. I., and Stahl, P. D. (1994) J. Biol. Chem. 269, 18720-18722[Abstract/Free Full Text]
  31. Jones, A. T., Mills, I. G., Scheidig, A. J., Alexandrov, K., and Clague, M. J. (1998) Mol. Biol. Cell 9, 323-332[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.